Valganciclovir for CMV in advanced HIV
Treatments studied
Part of Infections clinical trials.
This trial tests valganciclovir to see if it can reduce CMV virus in the blood for people with advanced HIV and a low CD4 count. It aims to prevent CMV from causing serious disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HIV with a CD4 count of 100 or lower.
- You must have CMV virus detected in your blood at a certain level.
- You cannot have active CMV disease, like retinitis (eye infection).
- You must not be pregnant or breastfeeding.
- Your blood counts and kidney and liver function must be good enough for the study drug.
- You must be able to swallow whole tablets and complete follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Hear when a new Cytomegalovirus (CMV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.